Lineage Cell Therapeutics Statistics

Total Valuation

TLV:LCTX has a market cap or net worth of ILS 1.15 billion. The enterprise value is 988.11 million.

Market Cap	1.15B
Enterprise Value	988.11M

Important Dates

The next estimated earnings date is Thursday, May 14, 2026.

Earnings Date	May 14, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	249.09M
Shares Outstanding	n/a
Shares Change (YoY)	+14.95%
Shares Change (QoQ)	+3.63%
Owned by Insiders (%)	5.00%
Owned by Institutions (%)	21.88%
Float	187.07M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	24.77
PB Ratio	8.32
P/TBV Ratio	165.63
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.88
EV / Sales	22.95
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-15.94

Financial Position

The company has a current ratio of 5.20, with a Debt / Equity ratio of 0.06.

Current Ratio	5.20
Quick Ratio	5.04
Debt / Equity	0.06
Debt / EBITDA	n/a
Debt / FCF	-0.12
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -105.30% and return on invested capital (ROIC) is -21.73%.

Return on Equity (ROE)	-105.30%
Return on Assets (ROA)	-12.06%
Return on Invested Capital (ROIC)	-21.73%
Return on Capital Employed (ROCE)	-21.52%
Weighted Average Cost of Capital (WACC)	14.06%
Revenue Per Employee	618,727
Profits Per Employee	-2.70M
Employee Count	75
Asset Turnover	0.13
Inventory Turnover	n/a

Taxes

Income Tax	-16.83M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +170.38% in the last 52 weeks. The beta is 1.80, so TLV:LCTX's price volatility has been higher than the market average.

Beta (5Y)	1.80
52-Week Price Change	+170.38%
50-Day Moving Average	515.47
200-Day Moving Average	492.16
Relative Strength Index (RSI)	46.61
Average Volume (20 Days)	3,231

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	21.48

Income Statement

In the last 12 months, TLV:LCTX had revenue of ILS 46.40 million and -202.54 million in losses. Loss per share was -0.88.

Revenue	46.40M
Gross Profit	-10.58M
Operating Income	-69.43M
Pretax Income	-218.85M
Net Income	-202.54M
EBITDA	-67.20M
EBIT	-69.43M
Loss Per Share	-0.88

Balance Sheet

The company has 177.83 million in cash and 7.71 million in debt, giving a net cash position of 170.12 million.

Cash & Cash Equivalents	177.83M
Total Debt	7.71M
Net Cash	170.12M
Net Cash Per Share	n/a
Equity (Book Value)	138.19M
Book Value Per Share	0.58
Working Capital	152.35M

Cash Flow

In the last 12 months, operating cash flow was -60.31 million and capital expenditures -1.66 million, giving a free cash flow of -61.98 million.

Operating Cash Flow	-60.31M
Capital Expenditures	-1.66M
Depreciation & Amortization	2.07M
Net Borrowing	-174,404
Free Cash Flow	-61.98M
FCF Per Share	n/a

Margins

Gross Margin	-22.80%
Operating Margin	-149.62%
Pretax Margin	-471.61%
Profit Margin	n/a
EBITDA Margin	-144.82%
EBIT Margin	-149.62%
FCF Margin	n/a

Dividends & Yields

TLV:LCTX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.95%
Shareholder Yield	-14.95%
Earnings Yield	-17.62%
FCF Yield	-5.39%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TLV:LCTX has an Altman Z-Score of -3.73 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.73
Piotroski F-Score	4